Jazz Pharmaceuticals (JAZZ) to Release Earnings on Wednesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) is scheduled to be releasing its earnings data after the market closes on Wednesday, November 6th. Analysts expect Jazz Pharmaceuticals to post earnings of $4.56 per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. On average, analysts expect Jazz Pharmaceuticals to post $16 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Jazz Pharmaceuticals Trading Up 0.5 %

Shares of JAZZ stock opened at $111.91 on Wednesday. The company has a 50 day moving average of $110.92 and a 200-day moving average of $109.53. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $134.48. The firm has a market cap of $7.06 billion, a P/E ratio of 23.07, a PEG ratio of 1.41 and a beta of 0.57.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on JAZZ. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Wells Fargo & Company reduced their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Finally, Piper Sandler reduced their price objective on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.43.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.